TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

May 1, 2027

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

multiTAA specific T cells

Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.

Trial Locations (3)

77030

Baylor Clinic, Houston

Houston Methodist Hospital, Houston

77054

Harris Health System - Smith Clinic, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Pancreatic Cancer Action Network

OTHER

collaborator

The V Foundation for Cancer Research

OTHER

collaborator

Harris County Hospital District

OTHER_GOV

lead

Baylor College of Medicine

OTHER

NCT03192462 - TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter